MILESTONE SCIENTIFIC INC (MLSS)

US59935P2092 - Common Stock

0.85  -0.02 (-2.3%)

After market: 0.8303 -0.02 (-2.32%)

Fundamental Rating

3

MLSS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. MLSS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MLSS is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MLSS has reported negative net income.
MLSS had a negative operating cash flow in the past year.
In the past 5 years MLSS always reported negative net income.
MLSS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -41.31%, MLSS is doing worse than 60.96% of the companies in the same industry.
With a Return On Equity value of -63.93%, MLSS perfoms like the industry average, outperforming 43.85% of the companies in the same industry.
Industry RankSector Rank
ROA -41.31%
ROE -63.93%
ROIC N/A
ROA(3y)-52.98%
ROA(5y)-62.22%
ROE(3y)-71.09%
ROE(5y)-140.19%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of MLSS (72.48%) is better than 82.89% of its industry peers.
In the last couple of years the Gross Margin of MLSS has grown nicely.
MLSS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.27%
GM growth 5Y8.46%

More info and screens

5

2. Health

2.1 Basic Checks

MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
MLSS has more shares outstanding than it did 1 year ago.
MLSS has more shares outstanding than it did 5 years ago.
MLSS has a better debt/assets ratio than last year.

2.2 Solvency

MLSS has an Altman-Z score of -6.18. This is a bad value and indicates that MLSS is not financially healthy and even has some risk of bankruptcy.
MLSS has a worse Altman-Z score (-6.18) than 73.26% of its industry peers.
MLSS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.18
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

MLSS has a Current Ratio of 2.85. This indicates that MLSS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.85, MLSS perfoms like the industry average, outperforming 52.41% of the companies in the same industry.
MLSS has a Quick Ratio of 1.59. This is a normal value and indicates that MLSS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MLSS (1.59) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 1.59

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.25% over the past year.
MLSS shows a decrease in Revenue. In the last year, the revenue decreased by -9.51%.
Measured over the past years, MLSS shows a small growth in Revenue. The Revenue has been growing by 0.43% on average per year.
EPS 1Y (TTM)40.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.65%
Revenue 1Y (TTM)-9.51%
Revenue growth 3Y21.79%
Revenue growth 5Y0.43%
Sales Q2Q%22.03%

3.2 Future

The Earnings Per Share is expected to grow by 22.47% on average over the next years. This is a very strong growth
Based on estimates for the next years, MLSS will show a small growth in Revenue. The Revenue will grow by 7.61% on average per year.
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.46%
Revenue Next 2Y3.75%
Revenue Next 3Y7.61%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MLSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MLSS's earnings are expected to grow with 22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MLSS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE SCIENTIFIC INC

NYSEARCA:MLSS (12/24/2024, 7:25:42 PM)

After market: 0.8303 -0.02 (-2.32%)

0.85

-0.02 (-2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners5.22%
Inst Owner Change4.97%
Ins Owners7.58%
Ins Owner Change1.51%
Market Cap66.21M
Analysts82.5
Price Target2.17 (155.29%)
Short Float %0.24%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-96.08%
Min EPS beat(2)-96.08%
Max EPS beat(2)-96.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.8%
Min Revenue beat(2)-27.95%
Max Revenue beat(2)-5.64%
Revenue beat(4)0
Avg Revenue beat(4)-18.2%
Min Revenue beat(4)-30.44%
Max Revenue beat(4)-5.64%
Revenue beat(8)2
Avg Revenue beat(8)-9.78%
Revenue beat(12)5
Avg Revenue beat(12)-8%
Revenue beat(16)7
Avg Revenue beat(16)-5.98%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.46
P/FCF N/A
P/OCF N/A
P/B 9.17
P/tB 9.37
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.31%
ROE -63.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.48%
FCFM N/A
ROA(3y)-52.98%
ROA(5y)-62.22%
ROE(3y)-71.09%
ROE(5y)-140.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.27%
GM growth 5Y8.46%
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.96%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.85
Quick Ratio 1.59
Altman-Z -6.18
F-Score4
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)17.69%
Cap/Depr(5y)17.06%
Cap/Sales(3y)0.12%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.65%
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.51%
Revenue growth 3Y21.79%
Revenue growth 5Y0.43%
Sales Q2Q%22.03%
Revenue Next Year-9.46%
Revenue Next 2Y3.75%
Revenue Next 3Y7.61%
Revenue Next 5YN/A
EBIT growth 1Y6.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.29%
OCF growth 3YN/A
OCF growth 5YN/A